checkAd

     153  0 Kommentare ADOCIA Announces Three Presentations at the American Diabetes Association 84th Scientific Sessions

    Regulatory News:

    Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, is pleased to announce that exclusive data from three of Adocia’s innovative technology platforms have been selected for poster presentations at the upcoming American Diabetes Association’s (ADA) 84th Scientific Sessions to be held June 21-24, 2024, in Orlando, Florida.

    The annual meeting of the ADA is the largest worldwide scientific meeting for clinicians and researchers in diabetes, obesity and metabolic disorders.

    The abstracts are published online on the journal Diabetes website and the ePoster presentations will be available to conference attendees from Friday, June 21, 2024. Posters will be displayed in the Poster Hall, West A4-B2.

    • AdoShell, a non-fibrotic encapsulation system for human islets transplantation shows promising results for clinical application as a cure for people with Type 1 Diabetes

    Xavier Gaume, Romain Besnard, Julie Brun, Nathalie Leclerc, Camille Gautier, Ouardane Jouannot, Nicolas Laurent, Anne-Lise Gaffuri, Rosy Eloy, Karim Bouzakri (CEED, Strasbourg, France), Olivier Soula

    • Presentation 1504-P: Saturday, June 22, 12:30 pm-1:30 pm (ET)

    AdoShell is an easily implantable and fully retrievable scaffold for islet transplantation aiming to cure diabetes by cell therapy without requiring immunosuppression. It is based on a permselective hydrogel film allowing insulin diffusion while preventing immune cell invasion. Allogenic transplant of rat islets in immunocompetent diabetic rats has already demonstrated encapsulated islets survival, insulin secretion, and glycemic regulation.

    Compatibility with human islets, local tolerance, and scalability to deliver a therapeutic dose were studied to meet requirements for a first in human. Findings of these studies demonstrate that AdoShell Islets is suitable for clinical evaluation.

    • AdOral, a versatile platform for improved oral peptide absorption

    Gregory Blache, Anne-Lise Gaffuri, Martin Gaudier, Sana Hakim, Audrey Maréchal, Ulysse Naessens, Romain Noël, Olivier Soula

    • Presentation 1677-P: Monday, June 24, 12:30 pm - 01:30 pm (ET)

    AdOral is an oral delivery platform based on non-specific Mechanism of Action (MoA) via intestine paracellular passage leading to improved absorption. AdOral‘s MoA and its permeation effect were evaluated in vitro and in vivo on several peptides, including semaglutide, and compared to SNAC (the technology used in Rybelsus). AdOral is a versatile and performant platform that could lead to oral formulations for a wide range of therapeutic peptides.

    Seite 1 von 3


    Diskutieren Sie über die enthaltenen Werte


    Business Wire (engl.)
    0 Follower
    Autor folgen

    ADOCIA Announces Three Presentations at the American Diabetes Association 84th Scientific Sessions Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, is pleased …